Stock Scorecard
Stock Summary for Neurocrine Biosciences Inc (NBIX) - $135.80 as of 1/12/2026 5:39:14 PM EST
Total Score
15 out of 30
Safety Score
67 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for NBIX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NBIX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NBIX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for NBIX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for NBIX (67 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 8 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 5 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for NBIX
Company Overview |
|
|---|---|
| Ticker | NBIX |
| Company Name | Neurocrine Biosciences Inc |
| Country | USA |
| Description | Neurocrine Biosciences, Inc. (NBIX), based in San Diego, California, is a leading biopharmaceutical company dedicated to developing innovative therapies for neurological, endocrine, and psychiatric disorders. The company boasts a robust pipeline aimed at addressing significant unmet medical needs, including treatments for Parkinson's disease and epilepsy. With a strong emphasis on scientific advancement and strategic partnerships, Neurocrine is well-positioned for sustainable growth in the biopharmaceutical industry, underlining its commitment to enhancing patient outcomes worldwide. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 135.80 |
| Price 4 Years Ago | 119.44 |
| Last Day Price Updated | 1/12/2026 5:39:14 PM EST |
| Last Day Volume | 1,419,297 |
| Average Daily Volume | 1,045,350 |
| 52-Week High | 160.18 |
| 52-Week Low | 84.23 |
| Last Price to 52 Week Low | 61.23% |
Valuation Measures |
|
| Trailing PE | 32.36 |
| Industry PE | 114.75 |
| Sector PE | 123.98 |
| 5-Year Average PE | 51.68 |
| Free Cash Flow Ratio | 39.82 |
| Industry Free Cash Flow Ratio | 12.83 |
| Sector Free Cash Flow Ratio | 29.04 |
| Current Ratio Most Recent Quarter | 3.38 |
| Total Cash Per Share | 3.41 |
| Book Value Per Share Most Recent Quarter | 30.13 |
| Price to Book Ratio | 4.67 |
| Industry Price to Book Ratio | 19.42 |
| Sector Price to Book Ratio | 24.69 |
| Price to Sales Ratio Twelve Trailing Months | 5.04 |
| Industry Price to Sales Ratio Twelve Trailing Months | 3.19 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.33 |
| Analyst Buy Ratings | 19 |
| Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
| Total Shares Outstanding | 99,706,000 |
| Market Capitalization | 13,540,074,800 |
| Institutional Ownership | 101.04% |
Dividends |
|
| Ex-Dividend Date | 12/29/1995 |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0400 |
| Total Years Dividend Increasing | 1 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.04 |
| Forward Annual Dividend Yield | 0.03% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 64.50% |
| Annual Earnings Growth | 36.68% |
| Reported EPS 12 Trailing Months | 4.19 |
| Reported EPS Past Year | 4.52 |
| Reported EPS Prior Year | 4.55 |
| Net Income Twelve Trailing Months | 428,000,000 |
| Net Income Past Year | 341,300,000 |
| Net Income Prior Year | 249,700,000 |
| Quarterly Revenue Growth YOY | 27.80% |
| 5-Year Revenue Growth | 24.48% |
| Operating Margin Twelve Trailing Months | 30.10% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 340,200,000 |
| Total Cash Past Year | 233,000,000 |
| Total Cash Prior Year | 251,100,000 |
| Net Cash Position Most Recent Quarter | 217,400,000 |
| Net Cash Position Past Year | 62,900,000 |
| Long Term Debt Past Year | 170,100,000 |
| Long Term Debt Prior Year | 170,100,000 |
| Total Debt Most Recent Quarter | 122,800,000 |
| Equity to Debt Ratio Past Year | 0.94 |
| Equity to Debt Ratio Most Recent Quarter | 0.96 |
| Total Stockholder Equity Past Year | 2,589,700,000 |
| Total Stockholder Equity Prior Year | 2,232,000,000 |
| Total Stockholder Equity Most Recent Quarter | 3,003,600,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 593,100,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 5.95 |
| Free Cash Flow Past Year | 557,200,000 |
| Free Cash Flow Prior Year | 361,600,000 |
Options |
|
| Put/Call Ratio | 0.20 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -3.19 |
| MACD Signal | -2.15 |
| 20-Day Bollinger Lower Band | 131.91 |
| 20-Day Bollinger Middle Band | 143.65 |
| 20-Day Bollinger Upper Band | 155.39 |
| Beta | 0.28 |
| RSI | 36.21 |
| 50-Day SMA | 129.70 |
| 150-Day SMA | 124.14 |
| 200-Day SMA | 119.13 |
System |
|
| Modified | 1/10/2026 4:09:28 AM EST |